diabetes glp-1 vs sglt2 Inhibitors and Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application APhA 2025: GLP-1 Receptor Agonists

Julie Berge: [00:10:23] Weve been off of shelves in Canada since early March, and thats a really big deal because Canada historically has been our number one export market, about 35 percent, which equates to about 1.1 billion in value in Canada

Functionally verifying the incretin receptor-dependent nature of the molecule, GLP-1GIPLani decreased body weight, food intake and blood glucose in DIO wild-type mice, and these effects were absent in DIO DIR-knockout mice (Fig

Particularly noteworthy is that in patients with both type 2 diabetes and MASLD, after 24 weeks of treatment with a 10 mg dose of efinopegdutide, liver fat content reduced by 72.7%, a result that is superior to the 42.3% reduction achieved with a 1 mg dose of semaglutide, despite a similar overall weight loss being observed with the two interventions

Semaglutide's long half-life means doubling injection frequency creates dangerously high blood levels without extra weight loss benefit